The in vitro activities of five new quinoline-carboxylic acids against 2 reference strains and 45 clinical isolates of Chlamydia trachomatis of genital origin were compared with the activities of minocycline and doxycycline. Ofloxacin was the third most active agent (after the two tetracyclines), followed by ciprofloxacin, Ofloxacin, a newly developed quinoline-carboxylic acid (quinolone) synthesized at Daiichi Seiyaku Co., Ltd., Tokyo, Japan, shows potent activity against a broad spectrum of gram-positive and gram-negative bacteria (10, 15). Moreover, in vitro studies demonstrated a high order of susceptibility of Neisseria gonorrhoeae to ofloxacin (11, 13). However, comparatively few studies have been done on the activity of this drug against Chlamydia trachomatis (2, 3, 9, 11, 16) . Therefore, we compared the in vitro activities of ofloxacin and four other quinoline-carboxylic acids with the activities of minocycline and doxycycline against 2 standard strains and 45 clinical isolates of C. trachomatis.
The in vitro activities of five new quinoline-carboxylic acids against 2 reference strains and 45 clinical isolates of Chlamydia trachomatis of genital origin were compared with the activities of minocycline and doxycycline. Ofloxacin was the third most active agent (after the two tetracyclines), followed by ciprofloxacin, NY-198, and AM-833.
Ofloxacin, a newly developed quinoline-carboxylic acid (quinolone) synthesized at Daiichi Seiyaku Co., Ltd., Tokyo, Japan, shows potent activity against a broad spectrum of gram-positive and gram-negative bacteria (10, 15) . Moreover, in vitro studies demonstrated a high order of susceptibility of Neisseria gonorrhoeae to ofloxacin (11, 13) . However, comparatively few studies have been done on the activity of this drug against Chlamydia trachomatis (2, 3, 9, 11, 16). Therefore, we compared the in vitro activities of ofloxacin and four other quinoline-carboxylic acids with the activities of minocycline and doxycycline against 2 standard strains and 45 clinical isolates of C. trachomatis.
The following antibiotics were obtained as standard powders: ofloxacin (Daiichi Seiyaku); ciprofloxacin (Bayer Yakuhin, Ltd., Osaka, Japan); norfloxacin (Kyorin Pharmaceutical Co., Ltd., Tokyo, Japan); AM-833 (Kyorin); NY-198 (Hokuriku Seiyaku Co., Ltd., Katsuyama, Fukui, Japan); doxycycline (Pfizer Taito Co., Ltd., Tokyo, Japan); and minocycline (Lederle Japan, Ltd., Tokyo, Japan).
The IFU of D-or F-strain organisms in 0.5 ml of maintenance medium. The maintenance medium was Dulbecco modified Eagle medium with 5% fetal calf serum and 1 ,ug of cycloheximide per ml. The plates were centrifuged for 60 min at 2,000 x g. The inoculant from each well was withdrawn with a Pasteur pipette and replaced with 1.0 ml of maintenance medium containing a dilution of antibiotic. Each concentration of antibiotic was tested in four monolayers. Serial * Corresponding author.
dilutions of 50 to 0.0125 ,ug of antibiotic per ml were used. After 72 h of incubation at 35°C, the cell cultures of each antibiotic dilution on cover slips in two wells were stained with iodine to identify inclusion bodies. The lowest concentration of each antibiotic which completely inhibited formation of inclusion bodies was considered the MIC. After 48 or 72 h of incubation, the medium was removed from each well without a cover slip and replaced with sucrose-phosphateglutamate medium. The cells were scraped off with a rubber spatula, frozen at -85°C, and thawed. To determine the minimal lethal concentration (MLC) by the method described by Heessen norfloxacin, 12.5 to 25.0. The results for the 45 clinical isolates were similar to those for the standard strains. The ranges of MICs of all antibiotics tested were very narrow. For example, the MIC of ofloxacin for the 45 clinical isolates was 0.39 ,ug/ml, and 100% of the isolates tested were inhibited at 0.78 ,ug/ml. The MICs of the four new quinolones other than norfloxacin were within a useful range.
In this study, numerous clinical isolates of C. trachomatis of genital origin were tested for susceptibility to new quinolones. The results of our tests of the antichlamydial activity of ciprofloxacin and the two tetracyclines were similar to those reported earlier (1, 2, 8, 11, 12, 14) . As expected, all of the clinical isolates of C. trachomatis were susceptible in vitro to the two tetracyclines and most of the new quinolones. It would be of great interest if a resistant chlamydial strain were to be identified in the future, as has occurred with other bacteria.
Ofloxacin has broad-spectrum activity against gram-positive and gram-negative bacteria. Ofloxacin and ciprofloxacin are also active in vitro against N. gonorrhoeae as well as mycoplasmas and ureaplasmas (1, 11, 13, 14, 17, 18) . 
